Study gives significant knowledge to forestalling worldwide pandemics Kumar Jeetendra | May 17, 2021 Whether it’s plankton exposed to parasites or people exposed to pathogens, a host’s initial immune response plays an integral role in determining whether infection occurs and to what level it spreads within a population, new University of Colorado Boulder research indicates. From parasitic flatworms transmitted by snails into individuals in developing nations, to zoonotic spillover …
Singapore endorses Pfizer-BioNTech COVID-19 antibody for use in 12 to 15-year-olds Kumar Jeetendra | May 18, 2021 Singapore has authorised the use of the Pfizer-BioNTech COVID-19 vaccine for those aged 12 to 15 years old in a bid to extend protection to more groups as the country tackles a recent increase of infections, officials said on Tuesday.“The data showed that the Pfizer-BioNTech COVID-19 vaccine demonstrated high efficacy consistent with that observed in …
Researchers develop experimental direct-acting antiviral treatment to treat COVID-19 Kumar Jeetendra | May 18, 2021 An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19. Conventional antivirals reduce symptoms and help people recover earlier. Examples …
India faces antifungal drug shortage as Black Fungus cases add to COVID-19 troubles Kumar Jeetendra | May 21, 2021 India said on May 21 that it is working to alleviate a shortage of a medicine used to treat a rare fungal disease hitting COVID-19 patients as the healthcare system is reeling under a massive wave of coronavirus infections. Cases of Mucormycosis, or Black Fungus, a potentially serious complication that causes blurred or double vision, …
Roche’s Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India Kumar Jeetendra | May 24, 2021 Mumbai, 24 May 2021: Roche India and Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as …
Bal Pharma dispatches antiviral drug Favipiravir at Rs 85/tablet Kumar Jeetendra | May 24, 2021 Drug maker Bal Pharma on Monday said it has launched antiviral drug Favipiravir in the domestic market under the brand name BALflu for the treatment of COVID-19. The Bengaluru-based company said its formulation would be available in tablet form with 400 mg strength. Favipiravir is being used for patients with mild to moderate COVID-19 infection as it …
New testing protocols for SARS-CoV-2 can handle a huge number of tests inside 48 hours Kumar Jeetendra | May 25, 2021 Researchers in the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is printed in the journal Nature Communications and might be adapted to many more pathogens. The COVID-19 pandemic has lasted more than a year and continues to …
More youngsters contaminated with COVID, no requirement for panic but important to immunize: Experts Kumar Jeetendra | May 25, 2021 More children are testing positive in the second Covid wave but the infection is mostly mild and the mortality rate low, say experts, citing increased testing and enhanced understanding of symptoms as among the possible reasons for the rising graph. Though there is enough anecdotal evidence of COVID-19 catching children – early teens and younger …
Another COVID-19 immunization enters last trial phase Kumar Jeetendra | May 27, 2021 Production of another potential vaccine against COVID-19 will begin within weeks, its developers Sanofi and GlaxoSmithKline said Thursday as they launched a large Phase III trial enrolling 35,000 adult volunteers in the United States, Asia, Africa and Latin America. The study will test the effectiveness of vaccine candidate formulas against the virus that spread from …
Bajaj Healthcare launches drug to treat black fungus infection in COVID-19 patients Kumar Jeetendra | May 28, 2021 Bajaj Healthcare on Friday launched Posaconazole API, used in treating Mucormycosis (black fungus) infection in COVID-19 patients. The company has received approval from FDA (Food and Drugs Administration) Gandhi Nagar, Gujarat (India), to manufacture and market Posaconazole API as approved medication for treating Mucormycosis in India, Bajaj Healthcare said in a regulatory filing. Bajaj Healthcare …
Moderna looks for full FDA endorsement for its COVID-19 vaccine Kumar Jeetendra | June 1, 2021 American pharmaceutical company Moderna says it has begun the process to win full U.S. regulatory approval for the use of its COVID-19 vaccine in adults. Moderna announced on Tuesday it has begun a “rolling submission” to the Food and Drug Administration of data from its studies of the two-dose vaccine. Moderna’s vaccine already has been …
We didn’t back multiplying of vaccine dosing gap: Indian researchers Kumar Jeetendra | June 16, 2021 The Indian government doubled the gap between the two doses of the AstraZeneca COVID-19 vaccine without the agreement of the scientific group that it said recommended the increase, three members of the advisory body told Reuters. The ministry of health announced the decision to change the gap from 6-8 weeks to 12-16 weeks on May …
